Opportunity radar
4,186,134 patents indexed · 165,974,948 citations · issued 2005-01-04 → 2026-05-05
Showing50 of 25,005
Pharma (A61K)Therapy methods (A61P)Med devices (A61M)Agriculture (A01)Hand tools (B25)Consumer (A47)Energy (H01M)AI / ML (G06N)
| Patent # | Title | Assets | Issued | Expires | Fwd cites | Score |
|---|---|---|---|---|---|---|
| 12565651 | Oligonucleotides comprising segmented gap structures | 🖼🧊📄§ | 2026-03-03 | 2044-07-10 | 0 | 31 |
| 12564641 | Eribulin antibody-drug conjugates and methods of use | 🖼🧊📄§ | 2026-03-03 | 2042-12-23 | 0 | 31 |
| 12564624 | Ostrich antibody for bacterial infectious diseases | 🖼🧊📄§ | 2026-03-03 | 2044-04-11 | 0 | 31 |
| 12564615 | Treatment method for cardiac hypertrophy | 🖼🧊📄§ | 2026-03-03 | 2043-12-19 | 0 | 31 |
| 12565537 | Compositions and methods targeting the nucleotide free state of RAS to block oncogenic signaling and transformation | 🖼🧊📄§ | 2026-03-03 | 2040-06-18 | 0 | 31 |
| 12565531 | Bispecific fusion protein for tumor treatment | 🖼🧊📄§ | 2026-03-03 | 2040-12-03 | 0 | 31 |
| 12564567 | Antiviral therapeutic compounds and compositions for use in treatment of coronavirus and influenza virus | 🖼🧊📄§ | 2026-03-03 | 2043-11-27 | 0 | 31 |
| 12564611 | Pancreatic endocrine progenitor cells and use thereof | 🖼🧊📄§ | 2026-03-03 | 2040-09-17 | 0 | 31 |
| 12565660 | Immunomodulating transgenic plants and related methods | 🖼🧊📄§ | 2026-03-03 | 2044-01-24 | 0 | 31 |
| 12564571 | Compositions and methods for the treatment of equine protozoal myeloencephalitis | 🖼🧊📄§ | 2026-03-03 | 2039-02-20 | 0 | 31 |
| 12564648 | Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors | 🖼🧊📄§ | 2026-03-03 | 2045-04-24 | 0 | 31 |
| 12564590 | Combinations of menin inhibitors and CYP3A4 inhibitors and methods of use thereof | 🖼🧊📄§ | 2026-03-03 | 2041-04-07 | 0 | 31 |
| 12564593 | Topical formulation for a JAK inhibitor | 🖼🧊📄§ | 2026-03-03 | 2045-07-18 | 0 | 31 |
| 12565522 | Micropeptide HMMW and application thereof | 🖼🧊📄§ | 2026-03-03 | 2040-11-03 | 0 | 31 |
| 12564626 | Serum free intracellular pathogen vaccine | 🖼🧊📄§ | 2026-03-03 | 2039-12-20 | 0 | 31 |
| 12564588 | HECT E3 ubiquitin liagase inhibitors and uses thereof | 🖼🧊📄§ | 2026-03-03 | 2042-01-21 | 0 | 31 |
| 12565533 | Agonistic CD40 antibodies | 🖼🧊📄§ | 2026-03-03 | 2043-05-25 | 0 | 31 |
| 12565653 | ATAXIN3 (ATXN3) RNAi agent compositions and methods of use thereof | 🖼🧊📄§ | 2026-03-03 | 2040-11-20 | 0 | 31 |
| 12564586 | Kappa opiod receptor antagonists for treating pain-related sleep disorders | 🖼🧊📄§ | 2026-03-03 | 2041-04-09 | 0 | 31 |
| 12565530 | Combination therapy with targeted 4-1BB (CD137) agonists/anti-FAP binding domain and anti-CEA/anti-CD3 bispecific antibody | 🖼🧊📄§ | 2026-03-03 | 2043-02-09 | 0 | 31 |
| 12565648 | MicroRNA-mediated methods for rejuvenating CNS glial populations | 🖼🧊📄§ | 2026-03-03 | 2042-10-19 | 0 | 31 |
| 12564642 | CEACAM5 antibody-drug conjugate formulation | 🖼🧊📄§ | 2026-03-03 | 2041-11-09 | 0 | 31 |
| 12565467 | Compounds, compositions, and methods for the treatment of inflammatory, degenerative, and neurodegenerative diseases | 🖼🧊📄§ | 2026-03-03 | 2043-12-12 | 0 | 31 |
| 12564566 | Uses of long-chain polyunsaturated fatty acids | 🖼🧊📄§ | 2026-03-03 | 2040-08-07 | 0 | 31 |
| 12559544 | Antibodies that bind human metapneumovirus fusion protein and their use | 🖼🧊📄§ | 2026-02-24 | 2040-05-20 | 0 | 31 |
| 12558333 | Agent for ameliorating and/or preventing sickle cell disease | 🖼🧊📄§ | 2026-02-24 | 2040-09-18 | 0 | 31 |
| 12558396 | Use of cyclo(His-Pro) (CHP) for preventing, alleviating or treating peritoneal fibrosis | 🖼🧊📄§ | 2026-02-24 | 2040-03-30 | 0 | 31 |
| 12559527 | Compositions comprising V2 opt HIV envelopes | 🖼🧊📄§ | 2026-02-24 | 2040-10-23 | 0 | 31 |
| 12558399 | Isocyclosporin A for topical treatment of ocular diseases | 🖼🧊📄§ | 2026-02-24 | 2042-12-22 | 0 | 31 |
| 12558327 | Methods and compositions for treating sleep apnea | 🖼🧊📄§ | 2026-02-24 | 2040-02-07 | 0 | 31 |
| 12558374 | Botanical film-forming acne compositions | 🖼🧊📄§ | 2026-02-24 | 2043-10-12 | 0 | 31 |
| 12558421 | Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof | 🖼🧊📄§ | 2026-02-24 | 2043-05-23 | 0 | 31 |
| 12559553 | IL-31 modulators for treating FXR-induced pruritus | 🖼🧊📄§ | 2026-02-24 | 2042-06-17 | 0 | 31 |
| 12558340 | ANAVEX2-73 for the treatment of genetic neurodevelopmental disorders | 🖼🧊📄§ | 2026-02-24 | 2042-01-21 | 0 | 31 |
| 12560596 | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy | 🖼🧊📄§ | 2026-02-24 | 2045-09-30 | 0 | 31 |
| 12559539 | TGF-beta receptor fusion protein pharmaceutical composition and use thereof | 🖼🧊📄§ | 2026-02-24 | 2039-11-08 | 0 | 31 |
| 12559569 | Methods of treating bleeding disorders by administration of chimeras comprising anti-von Willebrand factor antibodies and clotting factors | 🖼🧊📄§ | 2026-02-24 | 2042-12-20 | 0 | 31 |
| 12558350 | Compositions and methods for treatment | 🖼🧊📄§ | 2026-02-24 | 2042-07-27 | 0 | 31 |
| 12559523 | Compositions comprising chemerin analogs and methods of use | 🖼🧊📄§ | 2026-02-24 | 2040-07-29 | 0 | 31 |
| 12559525 | Conjugated fibronectin-binding peptides for use in tumor or fibrosis diagnosis and therapy | 🖼🧊📄§ | 2026-02-24 | 2042-10-05 | 0 | 31 |
| 12559563 | Müllerian inhibiting substance type 2 receptor (MISIIR)-specific CAR T cells for the treatment of ovarian cancer and other gynecologic malignancies | 🖼🧊📄§ | 2026-02-24 | 2040-04-14 | 0 | 31 |
| 12559532 | Embryonic angiogenesis markers and diagnostic and therapeutic strategies based thereon | 🖼🧊📄§ | 2026-02-24 | 2044-06-20 | 0 | 31 |
| 12558354 | Tumor necrosis factor alpha (TNF-alpha) small molecule inhibitor | 🖼🧊📄§ | 2026-02-24 | 2040-11-05 | 0 | 31 |
| 12558401 | Insulinotropic and glucagonotropic effects of beta-lactoglobulin | 🖼🧊📄§ | 2026-02-24 | 2040-11-20 | 0 | 31 |
| 12559458 | Co-crystals or salts of psilocin and methods of treatment therewith | 🖼🧊📄§ | 2026-02-24 | 2043-03-03 | 0 | 31 |
| 12559549 | Antibody binding to super-repressor IκB (srIκB) or antigen binding fragment thereof | 🖼🧊📄§ | 2026-02-24 | 2040-12-31 | 0 | 31 |
| 12558368 | Compositions and devices for systemic delivery of uridine | 🖼🧊📄§ | 2026-02-24 | 2039-02-01 | 0 | 31 |
| 12558325 | Methods for improving neurological diseases and disorders | 🖼🧊📄§ | 2026-02-24 | 2043-02-09 | 0 | 31 |
| 12558351 | Compositions and methods for enhancing cancer immune checkpoint therapy | 🖼🧊📄§ | 2026-02-24 | 2040-03-20 | 0 | 31 |
| 12558402 | Jellyfish collagen use | 🖼🧊📄§ | 2026-02-24 | 2041-06-15 | 0 | 31 |